Create your Personal Health Record and unlock support built around you

Aligned with your diagnosis, treatment and where you are in your care. It lets HealthTree show you:

Treatments and trials you qualify for
Education for your stage of care
Financial support for your medications
Solutions to your side effects

Learn more about HealthTree

Table of Contents

Posted by

HealthTree

Last updated and reviewed on: October 17, 2025

Understanding Bispecific Antibodies

Bispecific Antibodies or CAR T-cell Therapy?

Eligibility and Administration

Treatment Administration

Step-Up Dosing Explained

Transferring Care

Do I Need A Caregiver to Receive Bispecifics?

Early Access Programs

Treatment Course

Duration of Treatment

Side Effects of Bispecific Antibodies

General Safety Profile

Infection Risk (1/3)

Infection Risk (2/3)

Infection Risk (3/3)

Cytokine Release Syndrome (1/4)

Cytokine Release Syndrome (2/4)

Cytokine Release Syndrome (3/4)

Cytokine Release Syndrome (4/4)

Neurotoxicity and ICANS (1/2)

Neurotoxicity and ICANS (2/2)

Low Blood Cell Counts

T-cell Exhaustion

Teclistamab Side Effect Profile

Elranatamab Side Effect Profile

Talquetamab Side Effect Profile

Linvoseltamab Side Effect Profile

Side Effect Management and Support

ICANS Prevention

Infection Prevention (1/4)

Infection Prevention (2/4)

Infection Prevention (3/4)

Infection Prevention (4/4)

Keep Your Healthcare Team Informed

Quality of Life Impact

FDA Approved Bispecific Antibodies

Teclistamab (TECVAYLI)

Elranatamab (ELREXFIO)

Talquetamab (TALVEY)

Linvoseltamab (LYNOZYFIC)

Bispecific Antibodies in Clinical Trials

Bispecific Antibodies Clinical Trials

ABBV-383 (Abbvie)

Alnuctamab (BMS)

Cevostamab (Genentech)

Treatment Strategies with Bispecific Antibodies

Bispecific Combinations (1/2)

Bispecific Combinations (2/2)

Immunotherapy Treatment Sequencing (1/3)

Immunotherapy Treatment Sequencing (2/3)

Immunotherapy Treatment Sequencing (3/3)

Bispecifics for Newly Diagnosed Myeloma

Bispecifics in High-Risk Myeloma

Relapse on Bispecific Antibody Therapy

Refractory to Bispecific Antibody Therapy

Caregiver Role in Bispecific Antibody Therapy

Financial Resources for Bispecific Antibody Therapy

Pharmaceutical Support Resources

HealthTree Financial Resources

Future Considerations of Bispecific Antibody Therapy

Eliminating Disparities

Bispecifics in the Real World

Share Your Experience

Questions to Ask Your Doctor about Bispecific Antibody Therapy

Additional Resources

HealthTree Resources

External References

Related Content